Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Rift Valley fever monoclonal antibody therapeutic by IDBiologics

Next Previous
Trial Profile

A clinical trial of Rift Valley fever monoclonal antibody therapeutic by IDBiologics

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 26 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rift Valley fever monoclonal antibody therapeutic IDBiologics (Primary)
  • Indications Rift Valley fever
  • Focus Adverse reactions

Most Recent Events

  • 24 Aug 2024 According to an IDBiologics media release, the contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies (JPL CBRND-EB) within the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEOCBRND) of DOD under an Other Transaction Authority (OTA) for development of the RVFV antibodies through completion of Phase 1 human clinical studies.
  • 24 Aug 2024 New trial record
  • 12 May 2023 According to an IDBiologics media release, IDBiologics will lead preclinical safety and toxicology studies, development of a manufacturing process for the drug, production of the drug for clinical trials, and the execution of the Phase 1 clinical trial. The Global Pandemic Prevention and Biodefense Center (GPPBC) will be assisting with planning its late-stage development.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top